Zhangzhou Pientzehuang Pharmaceutical's second-quarter performance has slowed down and it wants to accelerate the creation of new "engines". | Speed reading announcement.
Zhangzhou Pientzehuang Pharmaceutical's revenue in the first half of the year was 5.65 billion yuan, a year-on-year increase of 11.99%; net income was 1.72 billion yuan, a year-on-year increase of 11.61%. Only in the second quarter, the year-on-year increase in revenue was only 2.61%, and net income decreased by 3.37% year-on-year. The company also released the "Improvement and Efficiency Return" action plan for 2024, which elaborates on key points to accelerate the creation of new engines for the company's development.
Tecsun Science & Technology (002908.SZ): The company is not currently involved in the business of csi old-age industry index.
Guangdong Tecsun Science & Technology (002908.SZ) stated on the investor platform on July 23rd that the company is not currently involved in the old-age industry business.
Express News | The CPC Central Committee: improve the population development support and service system, with a focus on responding to aging and dropping birth rates, and perfect the population development strategy.
Li Wenfeng has been approved as the new director of Xinhua Retirement. Investment income was weak in the first quarter, how to compete in the annuity market in the future?
① Li Wenfeng has taken up the position of the new party secretary of Xinhua Retirement since March; ② Xinhua Retirement suffered a net loss of 1.3 million yuan in the first quarter, with its investment yield ranking relatively low in the industry; ③ Under the trend of personal retirement pension system, how will Xinhua Retirement differentiate and innovate in the future?
Express News | Nearly 300 million seniors! Retirement in China is accelerating to become enjoyment in old age.
After the 483 form, Jiangsu Hengrui Pharmaceuticals received a warning letter from the FDA. The company claimed that the revenue from the site in question in the USA was very small.
Jiangsu Hengrui Pharmaceuticals received a warning letter from the FDA regarding issues with the quality control department's supervision and control of documents, as well as inadequate facility design. Hengrui Pharmaceuticals stated that this warning letter is related to the FDA Form 483 received in June and is expected to have no significant impact on the company's performance in 2024.